Radionuclide I-131 Labeled Albumin-Paclitaxel Nanoparticles for Synergistic Combined Chemo-radioisotope Therapy of Cancer

Tian, Longlong; Chen, Qian; Yi, Xuan; Wang, Guanglin; Chen, Jie; Ning, Ping; Yang, Kai; Liu, Zhuang

doi:10.7150/thno.17381

Cited by 86 publications

(59 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[212,213] Abraxane is an albumin based nanoparticles containing paclitaxel (130 nm) and has been clinically approved for the treatment of metastatic Albumin nanoparticles Paclitaxel [189][190][191] Poly(lactic-co-glycolic acid) nanoparitlces (PLGA) Paclitaxel, Etanidazole, 5-Fluorouracil, or NU7441 [124,[192][193][194][195][196] Cyclodextrin Camptothecin [188] Au nanoparticles Cisplatin or Trastuzumab [197][198][199] Mesoporous silica nanoparticles Cisplatin, Selenocystine, or Topotecan [200][201][202] UCNP-silica nanorattles Cisplatin or Docetaxel [57,61] Hollow or mesoporous TaOx nanoparticles 7-ethyl-10-hydroxycamptothecin or Doxorubicin [80,81] Chemo-RIT Liposomes 111 In -vinorelbine, 188 Re -doxorubicin, or 99 Y -paclitaxel [203][204][205][206][207] Polydopamine nanoparticles 131 I -Doxorubicin [156] Thermosensitive micelles 131 I -Doxorubicin [208] Albumin nanoparticles 131 I -Paclitaxel [150] Core-shell Bi 2 S 3 @mesoporous silica 32 P -Doxorubicin [67] www.advmat.de www.advancedsciencenews.com breast cancer. [212,213] Abraxane is an albumin based nanoparticles containing paclitaxel (130 nm) and has been clinically approved for the treatment of metastatic Albumin nanoparticles Paclitaxel [189][190]…”

Section: Polymeric Nanoparticles For Chemo-radiotherapymentioning

confidence: 99%

Emerging Nanotechnology and Advanced Materials for Cancer Radiation Therapy

et al. 2017

Self Cite

View full text Add to dashboard Cite

Radiation therapy (RT) including external beam radiotherapy (EBRT) and internal radioisotope therapy (RIT) has been widely used for clinical cancer treatment. However, owing to the low radiation absorption of tumors, high doses of ionizing radiations are often needed during RT, leading to severe damages to normal tissues adjacent to tumors. Meanwhile, the RT efficacies are limited by different mechanisms, among which the tumor hypoxia-associated radiation resistance is a well-known one, as there exists hypoxia inside most solid tumors while oxygen is essential to enhance radiation-induced DNA damages. With the development in nanotechnology, there have been great interests in using nanomedicine strategies to enhance radiation responses of tumors. Nanomaterials containing high-Z elements to absorb radiation rays (e.g. X-ray) can act as radio-sensitizers to deposit radiation energy within tumors and promote treatment efficacy. Nanoscale carriers are able to deliver therapeutic radioisotopes into tumors for internal RIT, or chemotherapeutic drugs for synergistically combined chemo-radiotherapy. As uncovered in recent studies, the tumor microenvironment could be modulated by various nanomedicine approaches to overcome hypoxia-associated radiation resistance. Herein, the authors will summarize the applications of nanomedicine for RT cancer treatment, and pay particular attention to the latest development of 'advanced materials' for enhanced cancer RT.

show abstract

Section: Polymeric Nanoparticles For Chemo-radiotherapymentioning

confidence: 99%

Emerging Nanotechnology and Advanced Materials for Cancer Radiation Therapy

et al. 2017

Self Cite

View full text Add to dashboard Cite

show abstract

“…For example, some chemotherapeutic agents (e.g., cisplatin, PTX, etc.) can amplify the localized X‐ray doses via the Compton scattering effect or trap the cells within the G2/M phase (most sensitive to ionizing radiation) to improve the radiotherapeutic effect for synergistic RT/chemotherapy . Some gasotransmitters (e.g., O 2 , NO, H 2 S, etc.)…”

Section: X‐ray‐excited Synchronous/synergistic Therapymentioning

confidence: 99%

Breaking the Depth Dependence by Nanotechnology‐Enhanced X‐Ray‐Excited Deep Cancer Theranostics

et al. 2019

View full text Add to dashboard Cite

treat cancer patients; however, it can cause severe systemic toxicity and immunesystem depression due to its nonspecific nature. [2][3][4] As a noninvasive therapeutic modality, radiotherapy (RT) with assistance from image guidance/positioning can be used to deliver X/γ-ray radiation to tumors. [5][6][7][8] This enables radiation oncologists to target malignant tissues for precise cancer therapy [9][10][11] while minimizing radiation dose delivered to surrounding normal tissues. However, RT efficacy can be attenuated by factors like salient hypoxia found in solid tumors. [12][13][14][15] Moreover, some cancer subtypes and cancer stem cells exhibit high resistance to X-ray radiation. [16] Consequently, the development of radiosensitizers that can sensitize hypoxic or radio-resistant tumors to X-ray radiation [17][18][19][20] has become an area of intense research.The emerging radiosensitizers can be classified into three groups: gasotransmitters (e.g., O 2 , NO, H 2 S, etc.), [21][22][23][24][25] anticancer drugs (e.g., paclitaxel (PTX), docetaxel (Dtxl), topotecan (TPT), etc.), [26][27][28] and high-Z elements (e.g., Au, Ba, Bi, Pt, W, etc.). [29][30][31][32][33][34][35] The gasotransmitters can mimic the radiosensitizing effect of oxygen and downregulate hypoxia-inducible factor-1 alpha (HIF-1α) expression, [23] while anticancer drugs can induce cancer cells to enter the G2/M phase which is the most radiation-sensitive cell-cycle phase. [36] High-Z elements are known for scattering one X-ray beam into several beams to concentrate more radiation on tumors for aggravated radiation damage. [37,38] This radiation dose-amplification effect is based on the Compton scattering mechanism. [39] All of these radiosensitizers are usually loaded or engineered into nanocarriers for tumor-specific delivery or by passive tumor accumulation via the enhanced permeability and retention (EPR) effect. [40] Heretofore, a great number of nanomaterials have been synthesized to pave the way for high-performance radiosensitization for RT enhancement. [41][42][43][44] Despite the appreciable progress achieved in X-ray radiation sensitization/enhancement, RT as a monotherapy generally fails to eliminate the whole tumor as cancer cells can undergo DNA-repair and regrowth. [45,46] As such, current research is gradually shifting from RT monotherapy to X-rayexcited multimodal therapy. This means that two or more therapeutic modalities are simultaneously activated by X-ray to yield synchronous/synergistic anticancer effects. [47][48][49] For example, it has been shown that high-energy X-ray irradiation can triggerThe advancements in nanotechnology have created multifunctional nanomaterials aimed at enhancing diagnostic accuracy and treatment efficacy for cancer. However, the ability to target deep-seated tumors remains one of the most critical challenges for certain nanomedicine applications. To this end, X-ray-excited theranostic techniques provide a means of overcoming the limits of light penetration and tissue attenuation. Herein, a comprehe...

show abstract

“…It was found that plain HSA‐CAT NRs exhibited negligible cytotoxicity toward 4T1 cells even at a high incubation concentration of 5 mg mL −1 in term of CAT for 24 h (Figure c), indicating them great biocompatibility. Then, by utilizing the abundant tyrosine residues in both HSA and CAT molecules, these HSA‐CAT NRs were efficient for the labeling of radioactive 131 I by adopting our previously used labeling methods . Then, the cell killing ability of such 131 I‐HSA‐CAT NRs was carefully compared with free 131 I by using the standard MTT assay.…”

Section: Resultsmentioning

confidence: 99%

“…Recently, various strategies by utilizing those nanoformulations with unique physiochemical properties have shown to efficiently attenuate tumor hypoxia and thus significantly increase the treatment outcomes of radiation therapy and other therapeutics . Regarding radionuclide therapy, it was shown that increased tumor oxygen delivery via photothermally boosted tumor blood perfusion or paclitaxel suppressed expression of hypoxia induced factor 1α (HIF‐1α) could thereby remarkably enhance the treatment outcomes of co‐delivered radioisotopes of Rhenium‐188 ( 188 Rh) and 131 I, respectively. In addition, in a recent work, it was shown that 131 I labeled human serum albumin (HSA)‐bound manganese dioxide nanoparticles ( 131 I‐HSA‐MnO 2 NPs) upon intravenous injection could enable superior tumor accumulation of 131 I via the enhanced permeability and retention (EPR) effect .…”

Section: Introductionmentioning

confidence: 99%

Hybrid Protein Nano‐Reactors Enable Simultaneous Increments of Tumor Oxygenation and Iodine‐131 Delivery for Enhanced Radionuclide Therapy

Chen

Liang

Song

et al. 2019

Small

Self Cite

View full text Add to dashboard Cite

It is hard for current radionuclide therapy to render solid tumors desirable therapeutic efficacy owing to insufficient tumor‐targeted delivery of radionuclides and severe tumor hypoxia. In this study, a biocompatible hybrid protein nanoreactor composed of human serum albumin (HSA) and catalase (CAT) molecules is constructed via glutaraldehyde‐mediated crosslinking. The obtained HSA‐CAT nanoreactors (NRs) show retained and well‐protected enzyme stability in catalyzing the decomposition of H2O2 and enable efficient labeling of therapeutic radionuclide iodine‐131 (131I). Then, it is uncovered that such HSA‐CAT NRs after being intravenously injected into tumor‐bearing mice exhibit efficient passive tumor accumulation as vividly visualized under the fluorescence imaging system and gamma camera. As the result, such HSA‐CAT NRs upon tumor accumulation would significantly attenuate tumor hypoxia by decomposing endogenous H2O2 produced by cancer cells to molecular oxygen, and thereby remarkably improve the therapeutic efficacy of radionuclide 131I. This study highlights the concise preparation of biocompatible protein nanoreactors with efficient tumor homing and hypoxia attenuation capacities, thus enabling greatly improved tumor radionuclide therapy with promising potential for future clinical translation.

show abstract

Radionuclide I-131 Labeled Albumin-Paclitaxel Nanoparticles for Synergistic Combined Chemo-radioisotope Therapy of Cancer

Cited by 86 publications

References 44 publications

Emerging Nanotechnology and Advanced Materials for Cancer Radiation Therapy

Emerging Nanotechnology and Advanced Materials for Cancer Radiation Therapy

Breaking the Depth Dependence by Nanotechnology‐Enhanced X‐Ray‐Excited Deep Cancer Theranostics

Hybrid Protein Nano‐Reactors Enable Simultaneous Increments of Tumor Oxygenation and Iodine‐131 Delivery for Enhanced Radionuclide Therapy

Contact Info

Product

Resources

About